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1 |  INTRODUCTION
Chronic kidney disease (CKD) is an important risk factor for 
cardiovascular and all-cause mortality. The 5-year survival rate 
among end-stage renal disease (ESRD) hemodialysis patients 
is nearly 50% (McGill, 2019) and most of these deaths are re-
lated to cardiovascular disease (CVD), making ESRD a cata-
strophic risk factor (Luft, 2000). Conceivably, the hemodialysis 
treatment per se has a counterproductive effect on cardiovascu-
lar risk. Oxylipins are a superclass of lipid mediators with po-
tent biological activities. They are derived from the oxidation 
of polyunsaturated fatty acids (PUFA). In addition to the well-
known eicosanoids derived from arachidonic acid (C20:4 n–6, 
AA), recent developments in lipidomics methodologies have 
raised awareness of, and interest in, the many hitherto unknown 
oxylipins. These products include octadecanoids derived from 
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Abstract
Chronic kidney disease (CKD) is an important risk factor for cardiovascular and all-
cause mortality. Survival rates among end-stage renal disease (ESRD) hemodialysis 
patients are poor and most deaths are related to cardiovascular disease. Oxylipins 
constitute a family of oxygenated natural products, formed from fatty acid by path-
ways involving at least one step of dioxygen-dependent oxidation. They are derived 
from polyunsaturated fatty acids (PUFAs) by cyclooxygenase (COX) enzymes, by li-
poxygenases (LOX) enzymes, or by cytochrome P450 epoxygenase. Oxylipins have 
physiological significance and some could be of regulatory importance. The effects 
of decreased renal function and dialysis treatment on oxylipin metabolism are un-
known. We studied 15 healthy persons and 15 CKD patients undergoing regular he-
modialysis treatments and measured oxylipins (HPLC-MS lipidomics) derived from 
cytochrome P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-
hydroxylase pathways in circulating blood. We found that all four subclasses of CYP 
epoxy metabolites were increased after the dialysis treatment. Rather than resulting 
from altered soluble epoxide hydrolase (sEH) activity, the oxylipins were released 
and accumulated in the circulation. Furthermore, hemodialysis did not change the 
majority of LOX/CYP ω/(ω-1)-hydroxylase metabolites. Our data support the idea 
that oxylipin profiles discriminate ESRD patients from normal controls and are influ-
enced by renal replacement therapies.
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linoleic acid (C18:2 n–6, LA) and α-linolenic acid (C18:3 
n–3, ALA), eicosanoids derived from dihomo-γ-linolenic acid 
(C20:3 n–6), eicosapentanoic acid (C20:5 n–3, EPA), and do-
cosanoids derived from adrenic acid (C22:4 n–6, AdA) or do-
cosahexaenoic acid (22:6 n–3, DHA) (Gabbs, 2015). Oxylipins 
are primarily produced via the cytochromes P450 (CYP) mono-
oxygenase, cyclooxygenase (COX), and lipoxygenase (LOX)/
CYP ω/(ω-1)-hydroxylase pathways (Figure 1), resulting in the 
formation of mono-, di-, and trihydroxy fatty acids, epoxy fatty 
acids, prostaglandins, thromboxanes, lipoxins, resolvins, and 
maresin (Gabbs, 2015). Epoxyoctadecenoic acids (EpOMEs), 
epoxyeicosatrienoic acids (EETs), epoxyeicosatetraenoic acids 
(EEQs), and epoxydocosapentaenoic acids (EDPs) represent 
the principal subclasses of CYP epoxygenase products. The 
primary metabolic fate of EETs (Figure 1), EpOMEs, EEQs, 
and EDPs in many cells is conversion into DHETs, DiHOMEs, 
DiHETEs, and DiHDPAs by the soluble epoxide hydrolase en-
zyme (sEH) (Spector, 2004).
F I G U R E  1  Cytochrome P450 epoxygenase (CYP) and 12- and 15-lipoxygenase (LOX)/ CYP (omega-1)-hydroxylase pathways 
evaluated in response hemodialysis. Linoleic (LA), arachidonic (AA), eicosapentaenoic (EPA), and docosahexaenoic acids (DHA) are 
converted to epoxyoctadecenoic acids (EpOMEs, e.g., 12,13-EpOME), epoxyeicosatrienoic acid (EETs), epoxyeicosatetraenoic acids (EEQs), 
and epoxydocosapentaenoic acids (EDPs) by CYP epoxygenase, respectively. EpOMEs, EETs, EEQs, and EDPs primary metabolic fate is 
conversion to dihydroxyctadecenoic acids (DiHOMEs, e.g., 12, 13-DiHOME), dihydroxyeicosatrienoic acids (DHETs, e.g., 5,6-DHET), 
dihydroxyeicosatetraenoic acids (DiHETEs, e.g., 5,6-DiHETE, 17,18-DiHETE) and dihydroxydocosapentaenoic acids (DiHDPAs, 19, 
20-DiHDPA), respectively, by the soluble epoxide hydrolase (sEH) enzyme. LA, AA, EPA, and DHA are converted to hydroperoxylinoleic 
acids (HpODEs), hydroxyoctadecadienoic acids (HODEs), leukotriene B (LTB), lipoxin A (LXA), hydroxydocosahexaenoic acids (HDHAs), 
hydroperoxyeicosatetraenoic acids (HPETEs), and hydroxyeicosatetraenoic acids (HETEs) by LOX, CYP omega/(omega-1)-hydroxylase and 
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Oxylipins are not only important in normal phys-
iology, but can also have detrimental effects (for review 
see (Gabbs,  2015; Nayeem,  2018; Tourdot, Ahmed, & 
Holinstat,  2014)). They could exhibit either beneficial 
or harmful cardiovascular effects (Afshinnia,  2018; Fan 
& Roman,  2017; Schunck,  2018). Oxylipin profiling of 
human plasma in uremic ESRD patients before fistula con-
struction surgery has been reported (Hu,  2018). The au-
thors identified decreases in 5,6-dihydroxyeicosatrienoic 
acid (5,6-DHET) and 5-hydroxyeicosatetraenoic acid (5-
HETE), but increases in 9,10-EpOME and 12,13-EpOME 
as key markers that discriminated between ESRD patients 
and controls. The products are biologically active. For ex-
ample, EETs and DHETs are considered candidates for 
vasodilatory endothelium-derived hyperpolarizing factors 
(EDHFs) (Campbell,  1996), whose release is triggered 
by Ca2+ and shear stress via the CYP pathway (Campbell 
& Fleming, 2010; Graber, Alfonso, & Gill,  1997). While 
EpOMEs and their diols decrease cardiac postischemic 
functional recovery (Bannehr, 2019a), 5-HETE stimulates 
neutrophil chemotaxis and degranulation, (Goetzl,  1980; 
Stenson & Parker, 1980; Valone, 1980) and inhibits endo-
thelial PGI2 production with consecutive effects on plate-
let aggregation and vasomotor tone (Gordon, Gordon, & 
Spector,  1991). Hemodialysis treatment per se increases 
levels of plasma 6-keto PGF1 alpha and PGF2 isopros-
tanes, which may also play a role in platelet aggregation 
and vasodilation (Kim,  2004; Kovac,  1992). Whether or 
not the hemodialysis treatment itself affects oxylipin pro-
files is unknown. We tested the hypothesis that oxylipin 
profiles differ in normal subjects and ESRD patients and 
that the hemodialysis treatment per se would affect plasma 
concentrations.
2 |  METHODS
The Charité University Medicine Institutional Review Board 
approved this registered study (ClinicalTrials.gov, Identifier: 
NCT03857984). In total, 15 healthy volunteers (6 male and 9 
female) and 15 ESRD patients (7 men and 8 women) partici-
pated in the study (Table 1). Inclusion criteria for the group of 
CKD patients were: history of renal failure requiring hemo-
dialysis/hemofiltration therapy, age over 18 years, the ability 
to consent, and written consent of the study participant. The 
patients in the group CKD were diagnosed for the follow-
ing conditions: diabetes mellitus (4 patients), hypertension 
(3 patients), membranous glomerulonephritis (2 patients), 
ADPKD (autosomal dominant polycystic kidney disease) (1 
patient), other or unknown (5 patients). Exclusion criteria for 
healthy volunteers were: age under 18 years, chronic illness 
requiring any medication, pregnancy, inability to follow sim-
ple instructions, relevant or severe abnormalities in medical 
history, or physical examination (Gollasch,  2020). Patients 
underwent thrice weekly dialysis, which lasted from 3  hr 
45 min to 5 hr, based on high flux AK 200 dialyzers (Gambro 
GmbH, Hechingen, Germany).
Venous blood was collected in each healthy subject by 
subcutaneous arm vein puncture in the sitting position. In 
the group of dialyzed patients (CKD group), all the blood 
samples were collected on the fistula arm right before begin-
ning of the dialysis (pre-HD) and at the end of the dialysis 
(5–15 min before termination, post-HD). All blood samples 
were obtained by 4°C precooled EDTA vacuum extraction 
tube systems. Cells were separated from plasma by centrif-
ugation for 10  min at 1,000–2,000 g using a refrigerated 
centrifuge. Following centrifugation, supernatant plasma 
was immediately transferred into clean polypropylene tubes 
using an Eppendorf pipette. The samples were maintained at 
2–8°C while handling. Aliquots (0.5 ml) were then stored at 
–80°C until further processing and extraction. Overall, the 
processing took no longer than 10 min. All samples were an-
alyzed for free and total plasma oxylipins. Oxylipins were 
determined by high-performance liquid chromatography 
mass spectrometry (HPLC-MS) spectrometry described in 
(Fischer, 2014) (Gollasch, 2019a). Descriptive statistics were 
T A B L E  1  Characteristics of hemodialysis (HD) patients and 
control subjects (n = 15 each)
HD patients Controls
Age (years) 50 ± 18 47 ± 12
Sex
Male (n) 7 6
Female (n) 8 9















Peripheral artery  
disease (n)
3
Note: Data are presented as mean ± SD or frequencies.
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calculated and variables were examined for meeting assump-
tions of normal distribution without skewness and kurtosis. 
We used the Shapiro–Wilk test to determine if they were 
normally distributed. In order to determine statistical signifi-
cance, a two-tailed t test or Mann–Whitney test were used to 
compare values of CKD versus control groups. Homogeneity 
of variances was asserted using Levene's test. Paired t test 
or paired Wilcoxon test were used to compare pre-HD ver-
sus post-HD values. In order to determine the statistical 
significance between the four classes of epoxy metabolites 
hydrolyzed to appear in the circulation, Friedman's test was 
used followed by applying Dunn's multiple comparison test 
(Gollasch, 2019a, 2019b). The .05 level of significance (p) 
was chosen. All data are presented as mean ± SD. All statis-
tical analyses were performed using SPSS Statistics software 
(IBM Corporation, Armonk, NY, USA).
3 |  RESULTS
3.1 | Clinical characteristics
Table 1 shows the demographics of the ESRD hemodialysis 
(HD) patients and control subjects. The results show that age 
and body mass indices between HD patients and the healthy 
subjects were not different (p  >  .05 each). Subjects were 
Caucasians, with the exception of one African and one Asian 
subject in each group. The ESRD patients had diabetes melli-
tus, hypertension, membranous glomerulonephritis, ADPKD, 
and other or unknown disease, as underlying causes. Major 
cardiovascular complications were cardiovascular and cer-
ebrovascular events, and peripheral artery disease.
3.2 | Oxylipins in ESRD
We first determined the total levels of oxylipins in plasma 
of the HD patients (Table 2) and compared the results with 
the healthy control subjects. We were particularly interested 
in 9,10-EpOME, 12,13-EpOME, 5,6-DHET, and 5-HETE, 
which have been recently identified as the key markers to dis-
criminate uremic ESRD patients from controls (Hu, 2018). 
Our results confirm these findings. However, we also detected 
increased 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET, 5,6-
EEQ, 11,12-EEQ, 14,15-EEQ, 17,18-EEQ, 14,15-DiHETE, 
7,8-EDP, 10,11-EDP, 16,17-EDP, 19,20-EDP, 5-HEPE, 12-
HEPE, and 19-HEPE levels in our ESRD patients undergo-
ing regular hemodialysis treatments, compared to the control 
subjects (Table 2A). Moreover, 13-HODE, 9,10-DiHOME, 
8,9-DHET, 11,12-DHET, 14,15-DHET, 8-HETE, 9-HETE, 
11-HETE, 12-HETE, 15-HETE, 16-HETE, 19-HETE, 20-
HETE, 8-HEPE, 9-HEPE, 15-HEPE, 18-HEPE, 4-HDHA, 
7-HDHA, 8-HDHA, 10-HDHA, 11-HDHA, 13-HDHA, 
14-HDHA, 16-HDHA, 17-HDHA,and 20-HDHA levels 
were decreased in our ESRD patients, compared to controls. 
Our dialysis patients showed 12,13-DiHOME, 8,9-EEQ, 
5,6-DiHETE, 8,9-DiHETE, 11,12-DiHETE, 17,18-DiHETE, 
13,14-EDP, 7,8-DiHDPA, 10,11- DiHDPA, 13,14- 
DiHDPA, 16,17- DiHDPA, 19,20- DiHDPA, 17-HETE, 18-
HETE, 12-HpETE, 20-HEPE, 21-HDHA, and 22-HDHA 
levels, which were similar to values observed in the control 
group. Metabolites in free state may have been contributed 
to changes of total 9,10-DiHOME, 11-HETE, 12-HETE, 
or 12-HEPE levels (Table 2B) since both total and free ox-
ylipins showed similar data grouping effects (right columns 
in Table 2A and B). With exception of decreased PGE2 and 
PGD2 levels (Table 2B), our CKD patients showed similar or 
nondetectable levels of TXB2, 11-dehydro TXB2, 15-keto-
PGE2, 13,14-dihydro-15-keto-PGE2, 13,14-dihydro-
15-keto-PGD2, PGJ2, 15-deoxy-delta 12,14-PGJ2, PGF2a, 
8-iso-PGF2a, TXB3, 11-dehydro TXB3, PGE3, 6(S)-LXA4, 
LXA4, 15(R)-LXA4, LXB4, LXA5, MAR 1, 7-epi-MAR1, 
RvD1, 17(R)-RvD1, RvD2, RvD3, RvD5, and RvE1, com-
pared to healthy controls (detection level of 0.05 ng/g, each).
Together, the findings indicate that ESRD is associated 
with an altered plasma oxylipins status namely an individual 
signature, which shows decreases in the majority of LOX/
CYP ω/(ω-1)-hydroxylase-dependent metabolites (HETEs, 
HEPEs, HDTAs, and 13-HODE) and increases in all four 
classes of CYP epoxy metabolites (i.e., EET, EpOME, EEQ, 
and EDP).
3.3 | Diol/epoxide ratios
As shown in Figure 1, the main pathway of EET, EpOME, 
EEQ, and EDP metabolism in many cells is conversion into 
DHETs, DiHOMEs, DiHETEs, and DiHDPAs by the soluble 
epoxide hydrolase enzyme (sEH), even though epoxy-poly-
unsaturated fatty acids (EpPUFA) can also be nonenzymati-
cally hydrolyzed into dihydroxymetabolites (DiHPUFA) 
(Spector,  2004). Since ESRD might have caused EET, 
EpOME, EEQ, and EDP production rapidly degraded to 
their diols, we next analyzed the sums of the individual CYP 
epoxy metabolites and their diols (Table 3A). We found that 
ESRD was associated with increased levels of the majority of 
those CYP metabolites (Table 3A). To provide insights into 
possible mechanisms underlying this increase, we calculated 
diol/epoxide ratios of the epoxy metabolites (Table 3B and 
C). We found that the four classes of epoxy metabolites are 
unequally hydrolyzed to appear in the circulation (Friedman's 
test, p  <  .05). We found that EpOMEs and EDPs are bet-
ter metabolized into their diols (ratio of DiHOMEs/EPOMEs 
and DiHDPAs/EDPs; 0.156 ± 0.301 and 0.114 ± 0.141, re-
spectively; Dunn's multiple comparison test, p  >  .05) than 
EETs and EEQs (ratios of those diols/epoxy metabolites, 
   | 5 of 24GOLLASCH et AL.
T A B L E  2  Comparison of oxylipins between control subjects versus. CKD patients before hemodialysis (HD) (n = 15)
Amount ng/mL Control (Mean ± SD) HD (mean ± SD)
p-value
t-Test
(#Mann-Whitney Test) Data grouping effect
A. Total oxylipins in plasma.
9,10-EpOME 17.22 ± 11.11 57.77 ± 53.82 .001# HD > Control
12,13-EpOME 19.42 ± 16.22 57.80 ± 58.55 .004#
5,6-EET 15.66 ± 7.34 47.09 ± 53.73 .013#
8,9-EET 4.97 ± 2.07 13.12 ± 13.52 .009#
11,12-EET 2.02 ± 064 7.29 ± 8.74 <.001#
14,15-EET 8.02 ± 3.62 35.11 ± 39.14 .001#
5,6-EEQ 7.87 ± 5.32 28.3 ± 32.4 .028
11,12-EEQ 0.42 ± 0.27 1.48 ± 1.60 .019#
14,15-EEQ 0.32 ± 0.20 1.22 ± 1.37 .011#
17,18-EEQ 1.00 ± 0.68 4.45 ± 4.74 .002#
14,15-DiHETE 0.02 ± 0.01 0.04 ± 0.09 .041#
7,8-EDP 1.53 ± 0.52 3.65 ± 2.36 .002#
10,11-EDP 0.33 ± 0.19 0.75 ± 0.54 .005#
16,17-EDP 1.33 ± 0.48 5.34 ± 4.55 <.001#
19,20-EDP 1.56 ± 0.55 7.75 ± 5.99 <.001#
5-HEPE 1.07 ± 0.62 1.12 ± 2.19 .023#
12-HEPE 1.09 ± 0.65 1.33 ± 3.32 .002#
19-HEPE 0.77 ± 0.31 1.80 ± 5.06 .021#
13-HODE 39.08 ± 13.32 30.44 ± 14.64 .041# HD < Control
9,10-DiHOME 5.05 ± 3.17 4.07 ± 4.37 .041#
5,6-DHET 1.60 ± 0.76 0.85 ± 0.45 .004#
8,9-DHET 1.42 ± 051 1.10 ± 1.25 .016#
11,12-DHET 0.41 ± 0.15 0.31 ± 0.16 .019#
14,15-DHET 0.55 ± 0.24 0.32 ± 0.10 .003
5-HETE 7.22 ± 3.21 4.25 ± 1.40 .001#
8-HETE 5.60 ± 2.41 3.16 ± 4.49 .003
9-HETE 6.60 ± 2.23 3.78 ± 1.38 <.001
11-HETE 9.95 ± 2.73 5.05 ± 1.53 <.001
12-HETE 11.82 ± 4.23 6.52 ± 3.42 <.001#
15-HETE 17.22 ± 5.36 8.82 ± 3.30 <.001
16-HETE 1.39 ± 0.61 0.75 ± 0.25 <.001#
19-HETE 1.10 ± 0.51 0.58 ± 0.22 <.001#
20-HETE 0.98 ± 0.30 0.72 ± 0.26 .019
8-HEPE 0.50 ± 0.28 0.46 ± 1.04 .001#
9-HEPE 0.53 ± 0.29 0.48 ± 1.05 .001#
15-HEPE 0.78 ± 0.44 0.66 ± 1.40 <.001#
4-HDHA 2.39 ± 0.95 1.61 ± 1.32 .009#
7-HDHA 1.04 ± 0.47 0.79 ± 0.88 .045#
8-HDHA 1.27 ± 0.55 1.02 ± 1.29 .026#
10-HDHA 1.75 ± 0.61 1.00 ± 1.00 .001#
11-HDHA 1.33 ± 0.57 0.97 ± 1.14 .013#
(Continues)
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Amount ng/mL Control (Mean ± SD) HD (mean ± SD)
p-value
t-Test
(#Mann-Whitney Test) Data grouping effect
13-HDHA 1.44 ± 0.54 0.90 ± 0.80 .002#
14-HDHA 2.27 ± 0.81 1.18 ± 1.33 .001#
16-HDHA 1.14 ± 0.40 0.76 ± 0.84 .002#
17-HDHA 3.02 ± 0.98 1.85 ± 1.83 .001#
20-HDHA 4.73 ± 1.78 2.90 ± 2.48 .002#
12,13-DiHOME 3.76 ± 1.67 3.18 ± 2.56 .267# No effect or not 
significant8,9-EEQ 0.66 ± 0.40 1.85 ± 2.03 .098#
5,6-DiHETE 0.25 ± 0.15 0.38 ± 0.69 .461#
8,9-DiHETE 0.02 ± 0.01 0.05 ± 0.14 .102#
11,12-DiHETE 0.01 ± 0.01 0.02 ± 0.07 .074#
17,18-DiHETE 0.10 ± 0.04 0.22 ± 0.48 .838#
13,14-EDP 0.20 ± 0.11 0.45 ± 0.40 .148#
7,8-DiHDPA 0.24 ± 0.13 0.28 ± 0.37 .412#
10,11-DiHDPA 0.05 ± 0.02 0.05 ± 0.09 .260#
13,14-DiHDPA 0.04 ± 0.01 0.04 ± 0.05 .130#
16,17-DiHDPA 0.10 ± 0.04 0.11 ± 0.11 .285#
19,20-DiHDPA 0.57 ± 0.25 0.90 ± 0.23 .935#
17-HETE 0.25 ± 0.07 0.30 ± 0.23 .967#
18-HETE 0.72 ± 0.36 0.56 ± 0.24 .187#
12-HpETE 6.23 ± 3.23 12.32 ± 10.44 .067#
20-HEPE 0.13 ± 0.07 0.35 ± 0.81 .775#
21-HDHA 0.70 ± 0.23 1.53 ± 3.35 .744#
22-HDHA 0.21 ± 0.07 0.63 ± 1.55 .967#
B. Free oxylipins in plasma.
13,14-EDP 0.01 ± 0.01 0.02 ± 0.02 .019# HD > Control
9-HEPE 0.04 ± 0.03 0.08 ± 0.25 .017#
12-HEPE 1.65 ± 1.25 3.26 ± 9.64 .015#
18-HEPE 0.38 ± 0.20 0.58 ± 1.67 .001#
10-HDHA 0.20 ± 0.10 0.23 ± 0.50 .029#
16-HDHA 0.06 ± 0.05 0.12 ± 0.37 .007#
17-HDHA 0.59 ± 0.28 0.85 ± 2.33 ,004#
9,10-DiHOME 1.65 ± 2.14 0.44 ± 0.41 .046 HD < Control
5,6-EET 0.37 ± 0.13 0.23 ± 0.10 .003
11,12-EET 0.06 ± 0.04 0.03 ± 0.02 .013#
14,15-DiHETE 0.03 ± 0.03 0.02 ± 0.05 .008#
17,18-DiHETE 0.27 ± 0.34 0.12 ± 0.20 .003#
9-HETE 0.12 ± 0.04 0.09 ± 0.12 .013#
11-HETE 0.74 ± 0.22 0.24 ± 0.12 <.001
12-HETE 9.61 ± 6.22 4.44 ± 5.60 .006#
15-HETE 1.19 ± 0.85 0.41 ± 0.22 <.001#
15-HEPE 0.14 ± 0.09 0.13 ± 0.35 .001#
13-HDHA 0.11 ± 0.07 0.10 ± 0.20 .022#
T A B L E  2  (Continued)
(Continues)
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Amount ng/mL Control (Mean ± SD) HD (mean ± SD)
p-value
t-Test
(#Mann-Whitney Test) Data grouping effect
14-HDHA 1.80 ± 0.96 1.30 ± 2.23 .017#
TXB2 0.38 ± 0.19 0.14 ± 0.16 .003#
PGE2 0.09 ± 0.04 0.04 ± 0.03 .001#
PGD2 0.05 ± 0.02 0.03 ± 0.02 .012#
13-HODE 7.68 ± 6.28 5.05 ± 5.27 .098# No effect or not 
significant
9,10-EpOME 0.70 ± 0.59 1.73 ± 2.01 .098#
12,13-EpOME 0.78 ± 0.70 1.59 ± 1.89 .254#
12,13-DiHOME 9.02 ± 14.34 2.93 ± 2.75 .080#
8,9-EET 0.02 ± 0.02 0.03 ± 0.03 .180
14,15-EET 0.31 ± 0.19 0.39 ± 0.28 .397
5,6-DHET 0.01 ± 0.01 0.01 ± 0.01 .856#
8,9-DHET 0.11 ± 0.12 0.09 ± 0.05 .719#
11,12-DHET 0.11 ± 0.09 0.08 ± 0.04 .555#
14,15-DHET 0.05 ± 0.02 0.04 ± 0.01 .067
5,6-EEQ 0.37 ± 0.12 0.32 ± 0.19 .688
8,9-EEQ 0.09 ± 0.08 0.35 ± 0.73 .241#
11,12-EEQ 0.02 ± 0.01 0.05 ± 0.12 1.000#
14,15-EEQ 0.09 ± 0.08 0.22 ± 0.59 .222#
17,18-EEQ 0.27 ± 0.22 0.75 ± 2.15 .467#
5,6-DiHETE 0.01 ± 0.01 0.01 ± 0.02 .098#
8,9-DiHETE 0.01 ± 0.01 0.01 ± 0.03 .896#
11,12-DiHETE 0.01 ± 0.01 0.01 ± 0.01 .047#
7,8-EDP 0.15 ± 0.8 0.15 ± 0.21 .235#
10,11-EDP 0.01 ± 0.01 0.03 ± 0.05 .316#
16,17-EDP−233 0.04 ± 0.06 0.02 ± 0.02 .185#
19,20-EDP 0.03 ± 0.04 0.49 ± 1.43 .072#
7,8-DiHDPA 0.01 ± 0.01 0.01 ± 0.01 .650#
10,11-DiHDPA 0.01 ± 0.01 0.01 ± 0.01 .200#
13,14-DiHDPA 0.01 ± 0.01 0.01 ± 0.01 .142#
16,17-DiHDPA 0.08 ± 0.05 0.09 ± 0.07 .717#
19,20-DiHDPA 0.34 ± 0.20 0.64 ± 0.81 .363#
5-HETE 0.07 ± 0.03 0.09 ± 0.11 .892#
8-HETE 0.17 ± 0.08 0.14 ± 0.09 .294#
16-HETE 0.29 ± 0.08 0.25 ± 0.10 .282
17-HETE 0.05 ± 0.02 0.11 ± 0.19 .928#
18-HETE 0.01 ± 0.01 0.03 ± 0.05 .339#
19-HETE 0.04 ± 0.01 0.04 ± 0.02 .690
20-HETE 0.25 ± 0.10 0.35 ± 0.19 .118#
12-HpETE 0.04 ± 0.04 0.05 ± 0.04 .598
5-HEPE 0.05 ± 0.03 0.15 ± 0.42 .440#
19-HEPE 0.35 ± 0.42 1.45 ± 4.24 .339#
20-HEPE 0.03 ± 0.06 0.24 ± 0.50 .823#
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0.047  ±  0.046 and 0.027  ±  0.031, respectively; Dunn's 
multiple comparison test, p  >  .05) (Table  3B). In fact, 
the following order of ratios was identified: DiHOMEs/
EpOMEs  =  DiHDPA/EDPs  >  DHETs/EETs  =  DiHETEs/
EEQs (Dunn's multiple comparison test, p < .05). This pat-
tern was also found for the individual metabolites in vivo, as 
shown (Table 3C). Together, the findings indicate that CYP 
epoxy metabolites are released and accumulated in the cir-
culation of ESRD HD patients, compared to controls, with 
epoxy metabolite substrate classes unequally hydrolyzed by 
sEH in vivo.
3.4 | Effects of hemodialysis
The effects of hemodialysis treatment on plasma oxylipins in 
ESRD HD patients are summarized (Table 4). The data demon-
strate an increase in the majority of epoxy metabolites, including 
9,10-EpOME, 12,13-EpOME, 9,10-DiHOME, 12,13-DiHOME, 
5,6-EET, 14,15-EET, 8,9-DHET, 11,12-DHET, 8,9-EEQ, 11,12-
EEQ, 14,15-EEQ, 17,18-EEQ, 14,15-DiHETE, 17,18-DiHETE, 
7,8-EDP, 10,11-EDP, 13,14-EDP, 16,17-EDP, 19,20-EDP, 
7,8-DiHDPA, 10,11-DiHDPA, 13,14-DiHDPA, 16,17-DiHDPA, 
and 19,20-DiHDPA (Table  4A). Moreover, hemodialysis also 
Amount ng/mL Control (Mean ± SD) HD (mean ± SD)
p-value
t-Test
(#Mann-Whitney Test) Data grouping effect
4-HDHA 0.03 ± 0.03 0.23 ± 0.73 .821#
7-HDHA 0.01 ± 0.01 0.05 ± 0.14 .294#
8-HDHA 0.02 ± 0.02 0.07 ± 0.19 .387#
11-HDHA 0.12 ± 0.07 0.28 ± 0.74 .254#
20-HDHA 0.16 ± 0.09 0.16 ± 0.37 .004#
21-HDHA 0.39 ± 0.51 2.02 ± 5.94 .892#
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T A B L E  3  Comparison of oxylipins and their ratios between control subjects versus. CKD patients before hemodialysis (HD) (n = 15)
Epoxides or Diols
(ng/mL) Control (Mean ± SD) HD (Mean ± SD)
p-value
Mann-Whitney test Data grouping effect
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Epoxides or Diols
(ng/mL) Control (Mean ± SD) HD (Mean ± SD)
p-value
Mann-Whitney test Data grouping effect
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Epoxides or Diols
(ng/mL) Control (Mean ± SD) HD (Mean ± SD)
p-value






















Ratios Control (Mean ± SD) HD (Mean ± SD)
p-value
Mann-Whitney test Data grouping effect
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increased several LOX/CYP ω/(ω-1)-hydroxylase metabolites, 
such as 13-HODE, 20-HETE, 5-HEPE, 15-HEPE, 18-HEPE, 
19-HEPE, 7-HDHA, and 11-HDHA. No changes occurred in 
the levels of other CYP and LOX/CYP ω/(ω-1)-hydroxylase 
metabolites (Table  4A). No level variations of free oxylipins 
were found in response to hemodialysis, with the exception of 
9,10-DiHOME, 11,12-EET, 19,20-DiHDPA, and 12-HpETE 
(Table  4B). While TXB2, PGE2, and PGD2 levels did not 
change by hemodialysis, this treatment did not cause accumula-
tion of detectable levels of 11-dehydro TXB2, 15-keto-PGE2, 
13,14-dihydro-15-keto-PGE2, 13,14-dihydro-15-keto-PGD2, 
PGJ2, 15-deoxy-delta 12,14-PGJ2, PGF2a, 8-iso-PGF2a, TXB3, 
11-dehydro TXB3, PGE3, 6(S)-LXA4, LXA4, 15(R)-LXA4, 
LXB4, LXA5, MAR 1, 7-epi-MAR1, RvD1, 17(R)-RvD1, 
RvD2, RvD3, RvD5, and RvE1 in plasma (Table 4B) at a detec-
tion level of 0.05 ng/g, each.
3.5 | Diol/epoxide ratios
Our analysis of sums of the individual CYP epoxy me-
tabolites and their diols (Table  5A) demonstrated increased 
accumulation of (9,10-EpOME  +  9,10-DiHOME), (12,13-
EpOME  +  12,13-DiHOME), (5,6-EET  +  5,6-DHET) 
(5,6-EEQ + 5,6-DiHETE), (8,9-EEQ + 8,9-DiHETE), (11,12-
EEQ  +  11,12-DiHETE), (14,15-EEQ  +  14,15-DiHETE), 
(17,18-EEQ  +  17,18-DiHETE), (7,8-EDP  +  7,8-DiHDPA), 
(19,20-EDP  +  19,20-DiHDPA), (8,9-EET  +  8,9-DHET), 
(14,15-EET + 14,15-DHET), (10,11-EDP + 10,11-DiHDPA), 
(13,14-EDP  +  13,14-DiHDPA) and (16,17-EDP  +   
16,17-DiHDPA). To provide insights into possible mecha-
nisms, we calculated ratios of diols/epoxides. We found that the 
ratios were not influenced by hemodialysis (Table 5B and C). 
Together, the results indicate that the CYP epoxy metabolites 
are rather released and accumulated in the circulation during 
hemodialysis treatment than resulting from altered sEH activ-
ity in vivo. Furthermore, hemodialysis treatment is insufficient 
to change the majority of LOX/CYP ω/(ω-1)-hydroxylase me-
tabolites in ESRD patients.
4 |  DISCUSSION
Our data demonstrate that all four subclasses of CYP epoxy 
metabolites and several LOX/CYP ω/(ω-1)-hydroxylase me-
tabolites are increased by the hemodialysis treatment. We 
found that these changes are unlikely related to altered sEH 
activity. The data are also not related to alterations of plasma 
or red blood cell (RBC) fatty acid levels, in particular RBC 
n-3 fatty acid status, which we demonstrated in our previous 
study (Gollasch, 2020). Despite significant changes in fatty 
acids signatures between healthy persons and CKD patients, 
we observed that hemodialysis does not alter plasma or RBC 
fatty acid levels to potentially explain the observed changes of 
oxylipins in the present study (Gollasch, 2020). Our data sup-
port the idea that 9,10-EpOME, 12,13-EpOME, 5,6-DHET, 
Ratios Control (Mean ± SD) HD (Mean ± SD)
p-value
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(#paired Wilcoxon Test) Data grouping effect
A. Total oxylipins in plasma.
13-HODE 30.44 ± 14.64 42.19 ± 23.88 .016# Post-HD
>
Pre-HD
9,10-EpOME 57.77 ± 53.82 145.71 ± 161.87 .041#
12,13-EpOME 57.80 ± 58.55 140.29 ± 145.06 .041#
9,10-DiHOME 4.07 ± 4.37 6.35 ± 4.81 .019#
12,13-DiHOME 3.18 ± 2.56 5.81 ± 3.71 .004#
5,6-EET 47.09 ± 53.73 127.44 ± 131.75 .035#
14,15-EET 35.11 ± 39.14 103.89 ± 115.46 .048#
8,9-DHET 1.10 ± 1.25 1.29 ± 1.49 .011#
11,12-DHET 0.31 ± 0.16 0.38 ± 0.19 .022#
8,9-EEQ 1.85 ± 2.03 5.27 ± 6.00 .019#
11,12-EEQ 1.48 ± 1.60 4.43 ± 5.59 .035#
14,15-EEQ 1.22 ± 1.37 3.56 ± 4.52 .030#
17,18-EEQ 4.45 ± 4.74 13.85 ± 18.04 .048#
14,15-DiHET 0.04 ± 0.09 0.05 ± 0.10 .019#
17,18-DiHETE 0.22 ± 0.48 0.25 ± 0.49 .006#
7,8-EDP 3.65 ± 2.36 9.67 ± 8.71 .041#
10,11-EDP 0.75 ± 0.54 1.98 ± 2.23 .041#
13,14-EDP 0.45 ± 0.40 1.33 ± 1.64 .048#
16,17-EDP 5.34 ± 4.55 17.46 ± 18.62 .041#
19,20-EDP 7.75 ± 5.99 26.39 ± 27.84 .035#
7,8-DiHDPA 0.28 ± 0.37 0.31 ± 0.40 .016#
10,11-DiHDPA 0.05 ± 0.09 0.06 ± 0.10 .011#
13,14-DiHDPA 0.04 ± 0.05 0.05 ± 0.05 .022#
16,17-DiHDPA 0.11 ± 0.11 0.13 ± 0.11 .002#
19,20-DiHDPA 0.90 ± 0.23 1.06 ± 1.17 .016#
20-HETE 0.72 ± 0.26 0.86 ± 0.26 .032
5-HEPE 1.12 ± 2.19 1.33 ± 2.63 .022#
15-HEPE 0.66 ± 1.40 0.78 ± 1.51 .013#
18-HEPE 1.78 ± 3.7 2.25 ± 4.58 .041#
7-HDHA 0.79 ± 0.88 0.91 ± 0.93 .048#
11-HDHA 0.97 ± 1.14 1.18 ± 1.27 .041#
19-HEPE 1.80 ± 5.06 1.62 ± 3.78 .041# Pre-HD
>
Post-HD
8,9-EET 13.12 ± 13.52 29.53 ± 27.79 .056# No effect or not 
significant
11,12-EET 7.29 ± 8.74 12.97 ± 11.42 .124#
5,6-DHET 0.85 ± 0.45 0.87 ± 0.40 .826#
14,15-DHET 0.32 ± 0.10 0.36 ± 0.10 .300
5,6-EEQ 28.3 + 32.4 87.0 + 114.0 .132
5,6-DiHETE 0.38 ± 0.69 0.42 ± 0.78 .272#
(Continues)








(#paired Wilcoxon Test) Data grouping effect
8,9-DiHETE 0.05 ± 0.1 0.06 ± 0.17 .221#
11,12-DiHETE 0.02 ± 0.07 0.03 ± 0.08 .109#
5-HETE 4.25 ± 1.40 4.84 ± 2.12 .213
8-HETE 3.16 ± 4.49 3.70 ± 1.75 .108
9-HETE 3.78 ± 1.38 4.83 ± 2.51 .083
11-HETE 5.05 ± 1.53 6.39 ± 3.21 .116
12-HETE 6.52 ± 3.42 7.11 ± 3.14 .158#
15-HETE 8.82 ± 3.30 10.82 ± 6.77 .109#
16-HETE 0.75 ± 0.25 0.92 ± 0.66 .221#
17-HETE 0.30 ± 0.23 0.33 ± 0.31 .363#
18-HETE 0.56 ± 0.24 0.56 ± 0.28 .638#
19-HETE 0.58 ± 0.2 0.58 ± 0.27 .925#
12-HpETE 12.32 ± 10.44 15.78 ± 19.17 .972#
8-HEPE 0.46 ± 1.04 0.54 ± 1.17 .096#
9-HEPE 0.48 ± 1.05 0.53 ± 1.08 .064#
12-HEPE 1.33 ± 3.32 1.52 ± 3.64 .064#
20-HEPE 0.35 ± 0.81 0.29 ± 0.49 .064#
4-HDHA 1.61 ± 1.32 1.94 ± 1.70 .084#
8-HDHA 1.02 ± 1.29 1.11 ± 1.32 .221#
10-HDHA 1.00 ± 1.00 1.16 ± 1.08 .056#
13-HDHA 0.90 ± 0.80 1.10 ± 0.93 .074#
14-HDHA 1.18 ± 1.33 1.42 ± 1.58 .064#
16-HDHA 0.76 ± 0.84 0.91 ± 0.92 .084#
17-HDHA 1.85 ± 1.83 2.26 ± 2.02 .084#
20-HDHA 2.90 ± 2.48 3.35 ± 3.00 .158#
21-HDHA 1.53 ± 3.35 1.29 ± 2.14 .925#
22-HDHA 0.63 ± 1.55 0.51 ± 0.81 .096#
B. Free oxylipins in plasma.
9,10-DiHOME 0.44 ± 0.41 1.07 ± 1.12 .034# Post-HD
>
Pre-HD
11,12-EET 0.03 ± 0.02 0.04 ± 0.02 .015#
19,20-DiHDPA 0.64 ± 0.81 0.69 ± 0.74 .019#
12-HpETE 0.05 ± 0.04 0.39 ± 0.36 .027
13-HODE 5.05 ± 5.27 9.23 ± 7.89 No effect or not 
significant
9,10-EpOME 1.73 ± 2.01 3.55 ± 2.62 .308#
12,13-EpOME 1.59 ± 1.89 4.28 ± 4.22 .272#
12,13-DiHOM 2.93 ± 2.75 6.10 ± 8.36 .099#
5,6-EET 0.23 ± 0.10 0.40 ± 0.32 .071#
8,9-EET 0.03 ± 0.03 0.02 ± 0.02 .347#
14,15-EET 0.39 ± 0.28 0.63 ± 0.66 .433#
5,6-DHET 0.01 ± 0.01 0.01 ± 0.01 .329
8,9-DHET 0.09 ± 0.05 0.10 ± 0.05 .131#
11,12-DHET 0.08 ± 0.04 0.09 ± 0.04 .306
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(#paired Wilcoxon Test) Data grouping effect
14,15-DHET 0.04 ± 0.01 0.05 ± 0.02
5,6-EEQ 0.32 ± 0.19 0.29 ± 0.34 .785
8,9-EEQ 0.35 ± 0.73 0.22 ± 0.26 .753#
11,12-EEQ 0.05 ± 0.12 0.02 ± 0.03 .310#
14,15-EEQ 0.22 ± 0.59 0.16 ± 0.28 .674#
17,18-EEQ 0.75 ± 2.15 0.50 ± 0.69 .071#
5,6-DiHETE 0.01 ± 0.02 0.01 ± 0.01 1.000#
8,9-DiHETE 0.01 ± 0.03 0.01 ± 0.02 .484#
11,12-DiHETE 0.01 ± 0.01 0.01 ± 0.01 .169#
14,15-DiHETE 0.02 ± 0.05 0.03 ± 0.04 .099#
17,18-DiHETE 0.12 ± 0.20 0.14 ± 0.19 .084#
7,8-EDP 0.15 ± 0.21 0.18 ± 0.17 .530#
10,11-EDP 0.03 ± 0.05 0.02 ± 0.02 .594#
13,14-EDP 0.02 ± 0.02 0.02 ± 0.01 .878#
16,17-EDP−233 0.02 ± 0.02 0.02 ± 0.02 .010#
19,20-EDP 0.49 ± 1.43 0.26 ± 0.46 .433#
7,8-DiHDPA 0.01 ± 0.01 0.01 ± 0.02 .272#
10,11-DiHDPA 0.01 ± 0.01 0.01 ± 0.01 .477#
13,14-DiHDPA 0.01 ± 0.01 0.01 ± 0.01 .218
16,17-DiHDPA 0.09 ± 0.07 0.10 ± 0.52 .136#
5-HETE 0.09 ± 0.11 0.08 ± 0.07 .530#
8-HETE 0.14 ± 0.09 0.14 ± 0.06 .695#
9-HETE 0.09 ± 0.12 0.09 ± 0.07 .388#
11-HETE 0.24 ± 0.12 0.25 ± 0.11 .893
12-HETE 4.44 ± 5.60 4.34 ± 3.23 .875#
15-HETE 0.41 ± 0.22 0.54 ± 0.29 .236
16-HETE 0.25 ± 0.10 0.30 ± 0.14 .209#
17-HETE 0.11 ± 0.19 0.11 ± 0.15 .530#
18-HETE 0.03 ± 0.05 0.03 ± 0.03 .875#
19-HETE 0.04 ± 0.02 0.04 ± 0.03 .068#
20-HETE 0.35 ± 0.19 0.39 ± 0.18 .695#
5-HEPE 0.15 ± 0.42 0.09 ± 0.12 .433#
8-HEPE 0.08 ± 0.23 0.07 ± 0.22 1.000#
9-HEPE 0.08 ± 0.25 0.05 ± 0.16 .754#
12-HEPE 3.26 ± 9.64 2.42 ± 7.17 1.000#
15-HEPE 0.13 ± 0.35 0.12 ± 0.28 .433#
18-HEPE 0.58 ± 1.67 0.44 ± 1.18 .814#
19-HEPE 1.45 ± 4.24 0.78 ± 1.35 .136#
20-HEPE 0.24 ± 0.50 0.09 ± 0.20 .893#
4-HDHA 0.23 ± 0.73 0.14 ± 0.40 .695#
-HDHA 0.05 ± 0.14 0.02 ± 0.05 .209#
8-HDHA 0.07 ± 0.19 0.04 ± 0.09 .272#
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and 5-HETE are key markers to discriminate ESRD patients 
from healthy controls (Hu,  2018). It is unlikely that these 
changes occurred in response to chronic dialysis treatment 
since altered levels in 9,10-EpOME, 12,13-EpOME, 5,6-
DHET, and 5-HETE levels were observed in patients with 
CKD before starting renal replacement therapy (Hu, 2018). 
While the ESRD patients in (Hu, 2018) were uremic Asians 
(eGFR 5–6 ml/min/1.73 m2) and recruited before beginning 
renal replacement therapy for fistula construction surgery, 
our patients were Caucasian ESRD patients undergoing regu-
lar, thrice weekly dialysis. Nonetheless, we observed similar 
changes in 9,10-EpOME, 12,13-EpOME, 5,6-DHET, and 
5-HETE levels. However, our study revealed also other ox-
ylipins that is, specific signature, which are up- or down-reg-
ulated in plasma of the ESRD patients. The extent to which 








(#paired Wilcoxon Test) Data grouping effect
10-HDHA 0.23 ± 0.50 0.18 ± 0.33 .583#
11-HDHA 0.28 ± 0.74 0.18 ± 0.34 .638#
13-HDHA 0.10 ± 0.20 0.08 ± 0.12 .814#
14-HDHA 1.30 ± 2.23 1.17 ± 1.61 .638#
16-HDHA 0.12 ± 0.37 0.09 ± 0.23 .182#
17-HDHA 0.85 ± 2.33 0.63 ± 1.24 .308#
20-HDHA 0.16 ± 0.37 0.12 ± 0.16 .136#
21-HDHA 2.02 ± 5.94 1.06 ± 2.35 .754#
22-HDHA 1.10 ± 3.00 0.61 ± 1.20 .638#
TXB2 0.14 ± 0.16 0.10 ± 0.08 .678#
11-dehydro TXB2 n.d. n.d.
PGE2 0.04 ± 0.03 0.03 ± 0.03 .540
15-keto-PGE2 n.d. n.d.
13,14-dihydro−15-keto-PGE2 n.d. n.d.
PGD2 0.03 ± 0.02 0.02 ± 0.01 .674#
13,14-dihydro−15-keto-PGD2 n.d. n.d.
PGJ2 n.d. n.d.
15-deoxy-delta 12,14-PGJ2 n.d. n.d.
PGF2a8-iso-PGF2a n.d. n.d.
TXB3 n.d. n.d.
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T A B L E  5  Effects of hemodialysis on oxylipins and their ratios in the CKD patients before (pre-HD) and at cessation (post-HD) of 
hemodialysis (n = 15)
Epoxides or Diols







































































8.01 ± 8.96 13.36 ± 11.42 .119 No effect or not 
significant
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Epoxides or Diols
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Epoxides or Diols


























Ratios Pre-HD (Mean ± SD) Post-HD (Mean ± SD)
p-value
Paired Wilcoxon test Data grouping effect






































T A B L E  5  (Continued)
(Continues)
20 of 24 |   GOLLASCH et AL.
possibly in metabolite-interacting networks, remains to be 
explored. Furthermore, future studies can clarify whether 
specific underlying renal diseases may have specific oxylipin 
profiles to discriminate between ESRD patients.
4.1 | CYP epoxy metabolites
Hemodialysis increased all four subclasses of CYP epoxy 
metabolites (9,10-EpOME, 12,13-EpOME, 9,10-DiHOME, 
12,13-DiHOME, 5,6-EET, 14,15-EET, 8,9-DHET, 11,12-DHET, 
8,9-EEQ, 11,12-EEQ, 14,15-EEQ, 17,18-EEQ, 14,15-DiHETE, 
17,18-DiHETE, 7,8-EDP, 10,11-EDP, 13,14-EDP, 16,17-EDP, 
19,20-EDP, 7,8-DiHDPA, 10,11-DiHDPA, 13,14-DiHDPA, 
16,17-DiHDPA, and 19,20-DiHDPA). Although these changes 
are unlikely related to altered sEH activity, but rather to the dialy-
sis treatment itself, reduced in vivo sEH activity in CKD/ESRD 
(Zhang, 2015) may have contributed to the increased accumu-
lation of all four epoxy metabolite classes in our CKD patients, 
compared to the healthy control subjects.
4.2 | EETs/DHETs
We demonstrated that hemodialysis increased EETs/DHETs 
levels, as detected for 5,6-EET, 14,15-EET, 8,9-DHET, 
and 11,12-DHET. Endothelial cells are reservoirs of EETs 
and the primary source of plasma EETs (Jiang, Anderson, 
& McGiff, 2010, 2012; Jiang, 2011; Schunck, 2017), which 
produce profibrinolysis and reduce inflammation, vascular 
tone, and blood pressure (Jiang, Anderson, & McGiff, 2010, 
2012; Jiang, 2011). 5,6-DHET as like 5,6-EET can produce 
vasodilation (Hercule, 2009; Lu, 2001), which could contrib-
ute to the cardiovascular response during maximal exercise 
(Gollasch,  2019a). The mechanisms of how epoxides and 
diols are released from the tissues and eventually become 
constituents of circulating lipoproteins are largely unknown, 
making it difficult to explain our findings. Cells preferen-
tially release DHETs while storing the EETs (Roman, 2002), 
suggesting that certain diols might be overrepresented in the 
circulating blood compared with the respective diol/epoxide 
ratios (Fischer, 2014). Our data support the idea that DHETs/
EETs are attractive signaling molecules for cardiovascu-
lar effects in ESRD because they are potent vasodilators 
(Campbell & Fleming, 2010), which could counteract circu-
lating vasoconstrictor substances during dialysis. Therapeutic 
sEH inhibition is considered a novel approach for enhanc-
ing the beneficial biological activity of EETs (Spector & 
Kim, 2015). However, presumably higher levels of EETs in 
blood and tissue in vivo may have also detrimental cardio-
vascular side effects (Gschwendtner, 2008; Hutchens, 2008; 
Wutzler, 2013). Of note, levels of all four EETs (5,6-EET, 
8,9-EET, 11,12-EET, and 14,15-EET) were high in the 
ESRD patients compared to the control. The extent to which 
this increase has beneficial or detrimental cardiovascular ef-
fects remains to be explored.
Ratios Pre-HD (Mean ± SD) Post-HD (Mean ± SD)
p-value
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4.3 | EpOMEs/DiHOMEs
We observed increases in 9,10-EpOME, 12,13-EpOME, 
9,10-DiHOME, and 12,13-DiHOME during dialysis. 9,10-
EpOME (leukotoxins A) and 12,13-EpOME (leukotoxin B) 
were initially found to be generated by neutrophils during 
the oxidative burst to combat bacterial infection (Thompson 
& Hammock, 2007). Recent findings suggest that EpOMEs 
exhibit cardiodepressant (Fukushima, 1988; Siegfried, 1990; 
Sugiyama,  1987) and vasoactive properties, the latter by 
endothelial NO and O(2)(*-) production (Okamura,  2002). 
Moreover, 9,10-EpOME and 12,13-EpOME can exhibit va-
soconstrictor responses in severe cardiac ischemia (Dudda, 
Spiteller, & Kobelt,  1996; Siegfried, 1990) and could con-
tribute to the cardiovascular response during maximal ex-
ercise (Gollasch, 2019a). New data suggest that DiHOMEs 
cause detrimental effects on postischemic cardiac function 
(Bannehr,  2019b; Chaudhary,  2013). Our data support the 
notion that increases in EpOMEs/DiHOMEs could affect car-
diac ischemia and hemodynamics in dialysis patients.
4.4 | EEQs/DiHETEs
We observed increases in 8,9-EEQ, 11,12-EEQ, 14,15-EEQ, 
17,18-EEQ, 14,15-DiHETE, and 17,18-DiHETE during dialy-
sis. While the putative biological functions of EEQs/DiHETEs 
have not received much attention, 17,18-EEQ has been iden-
tified as a potent vasodilator, which seems to be even more 
potent than EETs (Hercule,  2007; Lauterbach,  2002). Their 
diols could contribute to the cardiovascular response during 
maximal exercise (Gollasch, 2019a). The mechanisms of how 
EEQs/DiHETEs are released from the tissues are largely un-
known, making it difficult to explain our findings. Based on 
our calculations of diol/epoxide ratios, we have no evidence 
that the higher levels of 14,15-DiHETE, 17,18-DiHETE result 
from in vivo sEH enzyme activation. Nevertheless, the role 
of circulating EEQs/DiHETEs has yet to be integrated into a 
physiological and pathophysiological context. This is particu-
larly important since drugs that mimic 17,18-EEQ are viewed 
as novel promising drug candidates to overcome limitations of 
dietary EPA/DHA (C20:5 n–3/22:6 n–3) supplementation for 
cardiovascular health benefits (Schunck, 2017).
4.5 | EDPs/DiHDPAs
We observed increases in 7,8-EDP, 10,11-EDP, 13,14-EDP, 
16,17-EDP, 19,20-EDP, 7,8-DiHDPA, 10,11-DiHDPA, 
13,14-DiHDPA, 16,17-DiHDPA, and 19,20-DiHDPA dur-
ing dialysis. Little is known about the biological functions 
of EDPs/DiHDPAs. 16,17-EDP and 19,20-EDP are po-
tent vasodilators in coronary, pulmonary, and mesenteric 
arteries. They lower blood pressure and exhibit cardiopro-
tection by preservation of mitochondrial function (Morin, 
Fortin, & Rousseau, 2011; Schunck, 2017). Based on our 
calculations of diol/epoxide ratios, we have no evidence 
that the higher levels of DiHPAs metabolites observed 
in our study result from in vivo sEH enzyme activation. 
Our data indicate that both EDPs and DiHPAs metabo-
lites are novel candidates for vasoactive substances po-
tentially released by dialysis to affect hemodynamics in 
these conditions.
4.6 | LOX/CYP ω/(ω-1)-hydroxylase 
metabolites
We found that hemodialysis increased several LOX/CYP 
ω/(ω-1)-hydroxylase metabolites (13-HODE, 20-HETE, 
5-HEPE, 15-HEPE, 18-HEPE, 19-HEPE, 7-HDHA, and 11-
HDHA). Little is known about the biological functions of those 
metabolites. 13-HODE inhibits platelets (Buchanan,  1985) 
and could represent an important player in redox and immune 
homeostasis (Pecorelli, 2019; Vangaveti, 2018). 20-HETE is 
a potent vasoconstrictor, which modulates intracellular signal 
transduction pathways in neovascularization (Chen, 2019) and 
in renal and cardiac ischemia-reperfusion injury (Han, 2013; 
Hoff,  2011). Upregulation of 20-HETE contributes to in-
flammation, oxidative stress, endothelial dysfunction, and 
increased peripheral vascular resistance (Waldman,  2016). 
5-HEPE promotes bovine neutrophil chemotaxis in vitro, but 
less potently than 5-HETE (Heidel,  1989). 18-HEPE is re-
leased by macrophages to inhibit cardiac fibrosis and inflam-
mation in mice (Endo, 2014). Of note, 18-HEPE appears to 
downregulate proinflammatory and pro-proliferative factors, 
possibly via conversion to E-series resolvins (Sapieha, 2011). 
These resolvins have effects similar to the D-series resolvins, 
markedly reducing neutrophile infiltration, decreasing pro-
inflammatory cytokines, and enhancing the resolution of 
inflammation (Sapieha, 2011). We have no evidence that he-
modialysis affected resolvins, prostaglandins, thromboxanes, 
or other LOX/CYP ω/(ω-1)-hydroxylase metabolites in our 
patients (Shelmadine, 2017). Only few studies detected small 
changes in PGE2 or PGF2a (Losonczy, 1990; Schultze, 1984) 
and 5/12-HETE levels (Dolegowska, 2012) 4-HDHA is a me-
diator of antiangiogenic effects of n-3 PUFAs (Sapieha, 2011). 
Since we found that the majority of LOX metabolites meas-
ured were not affected by dialysis, we suggest that these me-
tabolites are unlikely to play important roles in this scenario.
5 |  CONCLUSIONS
To our knowledge, this is the first study to assess the impact 
of single hemodialysis treatment oxylipins in plasma using 
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large-scale lipidomics. We confirmed our hypothesis that 
the oxylipins status is influenced by hemodialysis treatment. 
Our data demonstrate that all four subclasses of CYP epoxy 
metabolites and a number of LOX/CYP ω/(ω-1)-hydroxylase 
metabolites are increased by the treatment. Moreover, ESRD 
patients undergoing regular dialysis show marked differ-
ences in plasma oxylipin profiles, that is, specific signatures, 
compared to control subjects. Future research is required to 
determine the contribution of the identified oxylipins in re-
ducing the risk from CVD in patients with kidney disease.
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